<div id="readability-page-1"><ul><li>Unusually High Volume Points to Upside in These Stocks</li></ul><p>Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings estimates for Candel Therapeutics in a report issued on Sunday, December 7th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.22) per share for the quarter. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.47) per share.</p><div><p><span></span><span>Get <strong>Candel Therapeutics</strong> alerts:</span></p></div><p>Several other brokerages have also recently issued reports on CADL. Lifesci Capital assumed coverage on Candel Therapeutics in a report on Tuesday, October 21st. They issued an &#34;outperform&#34; rating and a $16.00 target price on the stock. Citigroup decreased their price objective on Candel Therapeutics from $25.00 to $24.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, November 14th. Stephens  reissued an &#34;overweight&#34; rating and issued a $15.00 target price on shares of Candel Therapeutics in a report on Monday. Bank of America cut shares of Candel Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and reduced their price target for the stock from $13.00 to $7.00 in a research report on Wednesday, September 3rd. Finally, Wall Street Zen lowered shares of Candel Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th. One equities research analyst  has rated the stock with a Strong Buy rating, five have given a Buy rating, one  has given a Hold rating and one  has given a Sell rating to the company. According to MarketBeat.com, Candel Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $18.33.</p><p><b>Check Out Our Latest Stock Analysis on Candel Therapeutics</b></p><h2>Candel Therapeutics Price Performance</h2><p>Shares of NASDAQ:CADL opened at $5.66 on Wednesday. The firm has a market cap of $310.73 million, a price-to-earnings ratio of -9.93 and a beta of -0.92. Candel Therapeutics has a fifty-two week low of $4.25 and a fifty-two week high of $14.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.25 and a current ratio of 8.25. The firm has a fifty day moving average price of $5.22 and a 200 day moving average price of $5.50. </p><p>Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.04). </p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors have recently added to or reduced their stakes in CADL. BNP Paribas Financial Markets boosted its position in  Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company's stock valued at $40,000 after buying an additional 4,439 shares during the period.  Tower Research Capital LLC TRC boosted its holdings in shares of  Candel Therapeutics by 361.7% in the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company's stock valued at $49,000 after purchasing an additional 7,527 shares during the period.  Invesco Ltd. purchased a new stake in shares of  Candel Therapeutics in the 1st quarter worth $59,000.  AlphaQuest LLC bought a new position in shares of  Candel Therapeutics during the 1st quarter worth $61,000.  Finally, Taylor Financial Group Inc. raised its holdings in shares of  Candel Therapeutics by 36.0% in the third quarter. Taylor Financial Group Inc. now owns 13,600 shares of the company's stock valued at $69,000 after acquiring an additional 3,600 shares in the last quarter. Hedge funds and other institutional investors own  13.93% of the company's stock. </p><h2>Candel Therapeutics Company Profile</h2> (Get Free Report)<p>Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Candel Therapeutics</li><li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li><li>Insiders Are Selling These 3 Stocks—Here’s Why</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>Stock Market Upgrades: What Are They?</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li></ul> <p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Candel Therapeutics Right Now?</h2><p>Before you consider Candel Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.</p><p>While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CADL

<p>Brookline Capital Management estimates Candel Therapeutics will earn ($0.22) per share in Q4 2025. The stock has a consensus rating of "Moderate Buy" with a price target of $18.33. Recent ratings include "outperform" and "buy," but Bank of America downgraded it to "neutral." Institutional investors have adjusted their stakes, with hedge funds owning 13.93% of the stock. Candel Therapeutics develops immunotherapies for cancer, with several ongoing clinical trials.</p>

Brookline Capital Management Weighs in on CADL Q4 Earnings